POXEL SA: Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Results support the development of PXL770 in a Phase 2 clinical program for ADPKD Regulatory News: POXEL SA (Paris:POXEL) (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company

Related Keywords

Japan ,China ,Boston ,Massachusetts ,United States ,Tokyo ,France ,Arthur Rouill ,Dennis Riedl ,Sumitomo Pharma ,Davide Moller ,Kidney International ,Euronext ,Autosomal Dominant Polycystic Kidney ,Executive Vice President ,Chief Scientific Officer ,Euronext Paris ,Relations Communication Senior Director ,Vice President ,Investor Relations Communication ,Poxel ,Troxel ,Nnounces ,Publication ,Kidney ,Nternational ,Xl770 ,Reclinical ,Results ,Autosomal ,Dominant ,Polycystic ,Disease ,Adpkd ,